These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9706736)

  • 1. Using topiramate in patients with epilepsy: practical aspects.
    Sander JW
    Can J Neurol Sci; 1998 Aug; 25(3):S16-8. PubMed ID: 9706736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical aspects of the use of topiramate in patients with epilepsy.
    Sander JW
    Epilepsia; 1997; 38 Suppl 1():S56-8. PubMed ID: 9092962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmarketing experience with topiramate and cognition.
    Tatum WO; French JA; Faught E; Morris GL; Liporace J; Kanner A; Goff SL; Winters L; Fix A;
    Epilepsia; 2001 Sep; 42(9):1134-40. PubMed ID: 11580760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison.
    Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
    Seizure; 2008 Jan; 17(1):19-26. PubMed ID: 17618131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topiramate in refractory epilepsy: a prospective observational study.
    Stephen LJ; Sills GJ; Brodie MJ
    Epilepsia; 2000 Aug; 41(8):977-80. PubMed ID: 10961624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy.
    Lhatoo SD; Wong IC; Sander JW
    Epilepsia; 2000 Mar; 41(3):338-41. PubMed ID: 10714407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness and tolerability of topiramate in children with epilepsy under the age of 2 years: 4-year follow-up.
    Kim JM; Kwon S; Seo HE; Choe BH; Cho MH; Park SP
    J Korean Med Sci; 2009 Dec; 24(6):1078-82. PubMed ID: 19949663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy.
    Ben-Menachem E; Sander JW; Stefan H; Schwalen S; Schäuble B
    Clin Ther; 2008 Jul; 30(7):1180-95. PubMed ID: 18691980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pooled analysis of adjunctive topiramate in refractory partial epilepsy.
    Peeters K; Adriaenssen I; Wapenaar R; Neto W; Pledger G
    Acta Neurol Scand; 2003 Jul; 108(1):9-15. PubMed ID: 12807387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topiramate: a review of its use in the treatment of epilepsy.
    Lyseng-Williamson KA; Yang LP
    Drugs; 2007; 67(15):2231-56. PubMed ID: 17927286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial.
    Ramsay E; Faught E; Krumholz A; Naritoku D; Privitera M; Schwarzman L; Mao L; Wiegand F; Hulihan J;
    Epilepsia; 2010 Oct; 51(10):1970-7. PubMed ID: 20633037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
    Bootsma HP; Coolen F; Aldenkamp AP; Arends J; Diepman L; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M
    Epilepsy Behav; 2004 Jun; 5(3):380-7. PubMed ID: 15145308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topiramate and metabolic acidosis.
    Wilner A; Raymond K; Pollard R
    Epilepsia; 1999 Jun; 40(6):792-5. PubMed ID: 10368081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topiramate in patients with learning disability and refractory epilepsy.
    Kelly K; Stephen LJ; Sills GJ; Brodie MJ
    Epilepsia; 2002 Apr; 43(4):399-402. PubMed ID: 11952770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial.
    Naritoku DK; Hulihan JF; Schwarzman LK; Kamin M; Olson WH
    Ann Pharmacother; 2005 Mar; 39(3):418-23. PubMed ID: 15701778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topiramate titration to response: analysis of individualized therapy study (TRAITS).
    Dodson WE; Kamin M; Kraut L; Olson WH; Wu SC
    Ann Pharmacother; 2003 May; 37(5):615-20. PubMed ID: 12708932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topiramate: efficacy and tolerability in children according to epilepsy syndromes.
    Mikaeloff Y; de Saint-Martin A; Mancini J; Peudenier S; Pedespan JM; Vallée L; Motte J; Bourgeois M; Arzimanoglou A; Dulac O; Chiron C
    Epilepsy Res; 2003 Mar; 53(3):225-32. PubMed ID: 12694931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Antiepileptic Drugs on Cognition: Patient Perceived Cognitive Problems of Topiramate versus Levetiracetam in Clinical Practice.
    Bootsma HP; Aldenkamp AP; Diepman L; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M
    Epilepsia; 2006; 47 Suppl 2():24-7. PubMed ID: 17105455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy.
    Lhatoo SD; Wong IC; Polizzi G; Sander JW
    Epilepsia; 2000 Dec; 41(12):1592-6. PubMed ID: 11114218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topiramate and metabolic acidosis in infants and toddlers.
    Philippi H; Boor R; Reitter B
    Epilepsia; 2002 Jul; 43(7):744-7. PubMed ID: 12102678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.